Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?

Journal of Immunology

Volumn 168, Issue 2, 2002, Pages 651-660

  Cordaro, T A ^a   De Visser, K E ^a   Tirion, F H ^a   Schumacher, T N M ^a   Kruisbeek, A M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD8 ANTIGEN; NUCLEOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INFLUENZA VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSGENE; TUMOR IMMUNITY; TUMOR REJECTION;

EID: 0037080023     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.2.651     Document Type: Article

References (51)

1. T cell tolerance by clonal elimination in the thymus
2. + thymocytes
3. Positive and negative selection of an antigen receptor on T cells in transgenic mice
4. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen
5. Thymocyte selection: Not by TCR alone
6. T lymphocyte tolerance: From thymic deletion to peripheral control mechanisms
7. Public and private Vβ T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice
8. Positive and negative thymocyte selection induced by different concentrations of a single peptide
9. Low avidity recognition of self-antigen by T cells permits escape from central tolerance
10. Tolerance is overcome in beef insulin-transgenic mice by activation of low-affinity autoreactive T cells
11. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
12. Peripheral clonal elimination of functional T cells
13. Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity
14. Peripheral selection of the T cell repertoire
15. Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic β cells
16. Antigen presenting function of class II MHC expressing pancreatic β cells
17. Tolerance of class I histocompatibility antigens expressed extrathymically
18. Peripheral tolerance to allogeneic class II histocompatibility antigens expressed in transgenic mice: Evidence against clonal-deletion mechanism
19. T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I-E
20. Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice
21. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response
22. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction
23. Sigma variations: Observations on suppressor T cells and leprosy
24. Autoimmune diseases: The failure of self tolerance
25. A new look for the 1990s
26. T-cell antigens in cancer
27. Cancer antigens: Immune recognition of self and altered self
28. Human tumor antigens recognized by T lymphocytes
29. Induction of anti-self-immunity to cure cancer
30. Inducing autoimmune disease to treat cancer
31. Activation of low-avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity
32. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
33. + T lymphocytes
34. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
35. gp100/pmel 17 is a murine tumor rejection antigen: Induction of quot;self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
36. Tracing and characterization of the low-avidity-self-specific T cell repertoire
37. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands
38. Tolerance in TCR/cognate antigen double-transgenic mice mediated by incomplete thymic deletion and peripheral receptor downregulation
39. Studies in antibody response of mice to tumour inoculation
40. Inhibition of T cell and promotion of natural killer dell development by the dominant negative helix loop helix factor Id3
41. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs
42. Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells
43. Phenotypic analysis of antigen-specific T lymphocytes
44. Systemic T cell expansion during localized viral infection
45. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
46. + T cell response
47. Kinetics of the response of naive and memory CD8 T cells to antigen: Similarities and differences
48. + T cells to antigen stimulation in vivo
49. Cancer vaccines based on the identification of genes encoding cancer regression antigens
50. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
51. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease